Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market.
ANNONS
Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market.